Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) have been given a consensus rating of “Hold” by the thirty-three brokerages that are covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a sell rating, nineteen have given a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $19.41.

TEVA has been the topic of several research reports. TheStreet downgraded Teva Pharmaceutical Industries from a “c-” rating to a “d+” rating in a research report on Friday, August 25th. ValuEngine downgraded Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Friday, September 1st. Evercore ISI set a $38.00 target price on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Wednesday, October 25th. Cantor Fitzgerald set a $17.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Thursday, October 26th. Finally, Credit Suisse Group downgraded Teva Pharmaceutical Industries from a “neutral” rating to an “underperform” rating and cut their target price for the company from $25.00 to $13.00 in a research report on Wednesday, August 23rd.

Hedge funds have recently bought and sold shares of the company. Exane Derivatives purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $571,000. Korea Investment CORP boosted its stake in shares of Teva Pharmaceutical Industries by 14.3% during the 3rd quarter. Korea Investment CORP now owns 244,774 shares of the company’s stock worth $4,308,000 after acquiring an additional 30,674 shares in the last quarter. Financial Counselors Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 5.7% during the 2nd quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock worth $4,671,000 after acquiring an additional 7,571 shares in the last quarter. Private Capital Management Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 51.3% during the 3rd quarter. Private Capital Management Inc. now owns 26,100 shares of the company’s stock worth $459,000 after acquiring an additional 8,850 shares in the last quarter. Finally, Lockheed Martin Investment Management Co. purchased a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth about $317,000. 51.98% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries (TEVA) traded down $0.45 during midday trading on Friday, hitting $17.45. The company had a trading volume of 22,162,262 shares, compared to its average volume of 16,628,121. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries has a 52-week low of $10.85 and a 52-week high of $38.31. The firm has a market cap of $18,816.32, a P/E ratio of 4.28 and a beta of 0.55.

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were paid a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 1.95%. The ex-dividend date of this dividend was Monday, November 27th. Teva Pharmaceutical Industries’s payout ratio is currently -12.10%.

ILLEGAL ACTIVITY WARNING: “Teva Pharmaceutical Industries Ltd (TEVA) Receives Consensus Rating of “Hold” from Analysts” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/12/20/teva-pharmaceutical-industries-ltd-teva-receives-consensus-rating-of-hold-from-analysts.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.